CCM
PVLA

CAAS Capital Management’s Palvella Therapeutics PVLA Stock Holding History

CAAS Capital Management’s Portfolio PVLA Stock Details PVLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-754
Closed -$125K – 934
2020
Q3 		$125K Buy
+754
New +$172K ﹤0.01% 453

Other funds holding PVLA

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
ACM
Aquilo Capital Management San Francisco, California $55.8M AUM 41.76% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
CS
Candriam SCA Strassen, Luxembourg, Luxembourg $19.3B AUM 39.18% 1-Year Est. Return
TCM
Tekla Capital Management Boston, Massachusetts $2.56B AUM 18.15% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

CAAS Capital Management's PVLA Position: Q4 2020 in Review

CAAS Capital Management sold out of Palvella Therapeutics (PVLA) in Q4 2020, closing a stake of 754 shares — an estimated $125K sold.

CAAS Capital Management first reported a position in PVLA in Q3 2020 and held it in 1 quarter. The position peaked at $125K in Q3 2020. 82 funds tracked by Wall St. Rank hold PVLA as of Q4 2020.

  • CAAS Capital Management reported no remaining Palvella Therapeutics position as of Q4 2020 after selling out during the quarter.
  • CAAS Capital Management sold 754 Palvella Therapeutics shares in Q4 2020, an estimated $125K.
  • CAAS Capital Management first reported a position in Palvella Therapeutics in Q3 2020 and held it in 1 quarter.
  • CAAS Capital Management's Palvella Therapeutics position peaked at $125K in Q3 2020.
  • 82 funds tracked by Wall St. Rank held Palvella Therapeutics as of Q4 2020.

Based on CAAS Capital Management's 13F filing for Q4 2020, filed 12 Feb 2021.